{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:36:31Z","timestamp":1791020191272,"version":"4.1.0"},"reference-count":23,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>von Hippel-Lindau disease (VHL) is a multisystem cancer syndrome caused by mutations in the <jats:italic>VHL<\/jats:italic> gene. Retinal hemangioblastoma is one of the most common tumours, and when it appears near the optic nerve, its treatment is challenging and risky. To date, no treatment has proven effective in changing the course of the disease. This study was designed to evaluate the safety and effectiveness of propranolol in controlling these tumours.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Seven patients were included. All patients took a daily dose of 120 mg of propranolol for 1 year. Clinical variables were assessed at baseline, and at 1, 3, 6, 9 and 12 months. The primary endpoint of the study was the number and size of retinal hemangioblastomas. On every visit, retinal outcomes and blood biomarkers (such as vascular endothelial growth factor (VEGF) and miR210) were analysed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Number and size of retinal hemangioblastomas remained stable in all patients. All of them had initially increased levels of VEGF and miR210. There was a gradual reabsorption of retinal exudation in two patients, correlating with a progressive decrease of both biomarkers. The only adverse effect reported was hypotension in one patient.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Propranolol could be used to treat retinal hemangioblastomas in VHL patients, although more studies are needed to determine the ideal dose and long-term effect. VEGF and miR210 should be explored as biomarkers of disease activity. As far as we know, these are the first biomarkers proposed to monitor the VHL disease activity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>2014-003671-30<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjophth-2018-000203","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:25:45Z","timestamp":1559118345000},"page":"e000203","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Evaluation of the safety and effectiveness of oral propranolol in patients with von Hippel-Lindau disease and retinal hemangioblastomas: phase III clinical trial"],"prefix":"10.1136","volume":"4","author":[{"given":"Beatriz","family":"Gonz\u00e1lez-Rodr\u00edguez","sequence":"first","affiliation":[{"name":"Ophthalmology, Retina Service, Complejo Hospitalario de Toledo, Servicio de Salud de Castilla-La Mancha, Toledo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8346-6193","authenticated-orcid":false,"given":"Karina","family":"Villar G\u00f3mez de las Heras","sequence":"additional","affiliation":[{"name":"DG Asistencia Sanitaria, Servicio de Salud de Castilla-La Mancha, Toledo, Spain"},{"name":"Alianza VHL, Alianza de Familias de von Hippel-Lindau, Toledo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel T","family":"Aguirre","sequence":"additional","affiliation":[{"name":"Neurosurgery, Familial Neuro-Oncology Unit, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Rodr\u00edguez-Padial","sequence":"additional","affiliation":[{"name":"Cardiology, Complejo Hospitalario de Toledo, Servicio de Salud de Castilla-La Mancha, Toledo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Albi\u00f1ana","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Biol\u00f3gicas\u2014CIB, Centro Superior de Investigaciones Cient\u00edficas (CSIC), Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Recio-Poveda","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Biol\u00f3gicas\u2014CIB, Centro Superior de Investigaciones Cient\u00edficas (CSIC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel M","family":"Cuesta","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Biol\u00f3gicas\u2014CIB, Centro Superior de Investigaciones Cient\u00edficas (CSIC), Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa M\u00aa","family":"Botella","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Biol\u00f3gicas\u2014CIB, Centro Superior de Investigaciones Cient\u00edficas (CSIC), Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Mar\u00eda","family":"Jim\u00e9nez-Escribano","sequence":"additional","affiliation":[{"name":"Ophthalmology, Retina Service, Complejo Hospitalario de Toledo, Servicio de Salud de Castilla-La Mancha, Toledo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,5,28]]},"reference":[{"key":"2025090109321578000_4.1.e000203.1","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","article-title":"Von Hippel-Lindau disease","volume":"361","author":"Lonser","year":"2003","journal-title":"The Lancet"},{"key":"2025090109321578000_4.1.e000203.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.03.009"},{"key":"2025090109321578000_4.1.e000203.3","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.70.5.644"},{"key":"2025090109321578000_4.1.e000203.4","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.10320"},{"key":"2025090109321578000_4.1.e000203.5","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-015-0343-5","article-title":"Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients","volume":"10","author":"Albi\u00f1ana","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"2025090109321578000_4.1.e000203.6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1055\/s-0036-1579757","article-title":"Von Hippel-Lindau disease","volume":"5","author":"Findeis-Hosey","year":"2016","journal-title":"J Pediatr Genet"},{"key":"2025090109321578000_4.1.e000203.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(01)00245-4"},{"key":"2025090109321578000_4.1.e000203.8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/B978-0-444-62702-5.00010-X","article-title":"Von Hippel-Lindau disease","volume":"132","author":"Chittiboina","year":"2015","journal-title":"Handb Clin Neurol"},{"key":"2025090109321578000_4.1.e000203.9","first-page":"495","article-title":"Ocular manifestations of von Hippel-Lindau disease: clinical and genetic investigations","volume":"103","author":"Chew","year":"2005","journal-title":"Trans Am Ophthalmol Soc"},{"key":"2025090109321578000_4.1.e000203.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.04.033"},{"key":"2025090109321578000_4.1.e000203.11","doi-asserted-by":"crossref","unstructured":"Kanski JJ , Bowling B . Kanski\u2019s Clinical Ophthalmology. A Systematic Approach. Elsevier Health Sciences, 2011.","DOI":"10.1016\/B978-0-7020-4093-1.00019-7"},{"key":"2025090109321578000_4.1.e000203.12","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-017-0664-7","article-title":"Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease","volume":"12","author":"Albi\u00f1ana","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"2025090109321578000_4.1.e000203.13","unstructured":"Garc\u00eda-Sevilla J , Barturen F . F\u00e1rmacos que modifican la actividad simp\u00e1tica. In: Farmacolog\u00eda Humana. 3rd ed. Barcelona: Masson, 1997: 275\u20136."},{"key":"2025090109321578000_4.1.e000203.14","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.197"},{"key":"2025090109321578000_4.1.e000203.15","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.343"},{"key":"2025090109321578000_4.1.e000203.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.5422"},{"key":"2025090109321578000_4.1.e000203.17","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1505-3"},{"key":"2025090109321578000_4.1.e000203.18","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2908","article-title":"Propranolol for off-label treatment of patients with melanoma: results from a cohort study","volume":"4","author":"De Giorgi","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025090109321578000_4.1.e000203.19","doi-asserted-by":"crossref","first-page":"9567","DOI":"10.7314\/APJCP.2014.15.22.9567","article-title":"Are beta blockers new potential anticancer agents?","volume":"15","author":"Akbar","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"2025090109321578000_4.1.e000203.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09848.x"},{"key":"2025090109321578000_4.1.e000203.21","unstructured":"Karimi S , Nikkhah H , Ahmadieh H , et al . Intravitreal injection of propranolol for the treatment of retinal capillary hemangioma in a case of von Hippel\u2013Lindau. Retin Cases Br Rep 2018;0."},{"key":"2025090109321578000_4.1.e000203.22","doi-asserted-by":"crossref","first-page":"8228","DOI":"10.1167\/iovs.15-17169","article-title":"Ocular safety of intravitreal propranolol and its efficacy in attenuation of choroidal neovascularization","volume":"56","author":"Nourinia","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2025090109321578000_4.1.e000203.23","doi-asserted-by":"crossref","unstructured":"Shepard MJ , Bugarini A , Edwards NA , et al . Repurposing propranolol as an antitumor agent in von Hippel-Lindau disease. J Neurosurg 2018;(Oct 26):1\u20139.doi:10.3171\/2018.5.JNS172879","DOI":"10.3171\/2018.5.JNS172879"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2018-000203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:32:27Z","timestamp":1756744347000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2018-000203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,5,28]]},"published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1136\/bmjophth-2018-000203"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2018-000203","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}